Hadasit

What Hadasit does

Hadasit is the technology transfer and venture building company of Hadassah Medical Center in Jerusalem, founded in 1986. The company commercializes medical technologies developed at Hadassah University Medical Center, operating across pharmaceuticals, molecular diagnostics, life sciences, and medical devices/digital health. Its core platform comprises a Data Research Center with unified clinical data repositories, GMP-compliant manufacturing facilities, a portfolio of specialized research institutes (Liver Institute, Wohl Institute for Translational Medicine, Hadassah Organoid Center, Hadassah Cancer Research Institute, BrainLabs), the Hadassah Accelerator (powered by IBM Alpha Zone), and JumpStart Funding programs. Hadasit manages a portfolio of more than 20 spin-off and licensed companies, including Periochip, PathKeeper, Gamida Cell (Omisirge), NeuroGenesis (NG-01), Cell Cure Neurosciences, PlasFree, and CMVista, with multiple portfolio assets holding FDA approvals or clearances.

The company's business model rests on three revenue streams: technology licensing and royalty arrangements with pharmaceutical, biotech, and medical device companies; venture building and equity returns through its TASE-listed subsidiary Hadasit Bio-Holdings (HBL, ticker HDST); and fee-for-service R&D, laboratory services, and collaborative research arrangements. Hadasit sells into three primary customer segments: pharmaceutical companies (Moderna, Genentech via Lineage, BioTime, Recipharm), biotech and medical device startups (Pangea Biomed, Ultima Genomics, MyBiotics, SHL Telemedicine, Enlivex, Kahr Bio), and academic/research institutions. Distribution is enterprise-field-sales driven, supplemented by the Hadassah Accelerator program and direct spin-off formation. Pricing is bespoke and not publicly disclosed. Strategic investors include Centaurus Investment (advised by Consensus Business Group) and Korea Investment Partners. Recent strategic actions include an exclusive Genentech collaboration on OpRegen RPE cell therapy (December 2025), a TechsoMed AI partnership (July 2025), and a Moderna-sponsored cCMV research collaboration (July 2024), alongside multiple FDA regulatory milestones across the portfolio.

Name

Hadasit

Legal name

Hadasit - Hadassah Technology Transfer

Website

https://hadasit.org.il

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

11–50 employees

Short description

Hadasit is the technology transfer and venture building company of Hadassah Medical Center in Jerusalem, commercializing medical technologies through licensing, spin-offs, and R&D services. It serves global pharmaceutical, biotech, and medical device companies across a portfolio of more than 20 companies.

Ownership category

akta.pro rank

Product category

Medical Technology Transfer

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL)

akta.pro secondary industries

mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Quality Engineering & Risk Management (ICH Q9/Q10, validation, change control) (HLAGAKAL)

Keywords

• Medical technology transfer
• Biotech venture building
• Pharmaceutical licensing
• Clinical research services
• Healthcare innovation

Headquarters

HQ city

Jerusalem

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Technology Licensing: Licensing of medical technologies and intellectual property developed at Hadassah Medical Center to pharmaceutical, biotech, and medical device companies
2. Venture Building and Portfolio Investment: Creation and investment in spin-off companies through Hadasit Bio-Holdings (HBL), generating returns through equity appreciation and exit events
3. R&D Services and Collaboration: Fee-for-service laboratory research, consulting, and collaborative research arrangements with industry partners

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Hadasit commercializes medical technologies and intellectual property developed at Hadassah University Medical Center through direct licensing to pharmaceutical, biotech, and medical device companies; creation and investment in spin-off companies via its publicly listed subsidiary Hadasit Bio-Holdings (HBL); and fee-for-service R&D, laboratory, and clinical research collaborations. It also operates a digital health/medical device accelerator program (Hadassah Accelerator, powered by IBM Alpha Zone) and runs specialized research facilities including a Data Research Center, GMP manufacturing, pathology, liver, organoid, cancer, and psychedelic research centers.

Product overview

Hadasit is Hadassah University Medical Center's technology transfer and venture building company that commercializes medical technologies. The organization operates as a technology transfer office managing a portfolio of spin-off companies, providing R&D services and laboratory facilities, and facilitating licensing of medical innovations. The portfolio spans pharmaceuticals (including DOXIL, novel cancer therapies, cell therapies), molecular diagnostics, medical devices (including Periochip, PathKeeper navigation system, Fidmi Medical feeding devices), and digital health technologies. Core services include the Hadassah Accelerator program for digital health startups, Data Research Center for clinical data access, GMP production facilities, and various laboratory services. The organization also operates the Hadassah BioMed Innovation Day conference series and provides funding support through JumpStart Funding programs.

Differentiator

Problem solved

Functional benefit

Products and services

• Hadassah Accelerator A 6-month acceleration program for digital health and medical device startups, powered by IBM Alpha Zone. Provides mentorship, Hadassah expert access, IBM specialist support, and exposure to strategic investors. First 11 graduates raised approximately $10M in investment and grants.
• Data Research Center Provides unified data repositories and clinical data access for researchers, physicians, and technology companies. Part of Israel's National AI R&D Infrastructure Program for accelerating AI-driven breakthroughs.
• JumpStart Funding Early-stage funding program to support researchers and innovators in developing medical technologies from concept to commercialization.
• GMP Facility Good Manufacturing Practice compliant facility for producing clinical-grade cell therapies, pharmaceuticals, and biological products.
• Pathology Department Services Comprehensive diagnostic services including molecular laboratories for DNA/RNA sequencing, biomarker discovery, and precision diagnostics. CAP-accredited; processes approximately 45,000 tissue/cytology cases and ~1,000 molecular cases annually.
• Liver Institute and Research Center Specializes in molecular and immunological aspects of liver disease pathogenesis, identifying checkpoints for therapeutic outcomes. Includes patient clinical data and liver tissue biobank. Performs GLP/GMP lab tests for clinical trials per ISO standards.
• Hadassah Organoid Center Organoid technology development and applications in precision medicine and drug testing, led by Dr. Myriam Grunewald.
• Hadassah Cancer Research Institute Comprehensive cancer research facility developing immunotherapy, CAR-T therapies, and novel cancer treatments in collaboration with industry partners.
• BrainLabs - Center for Psychedelic Research Psychedelic research for neuropsychiatric conditions including OCD treatment using psilocybin, directed by Prof. Bernard Lerer.
• PathKeeper Spinal Surgery Navigation System FDA-cleared spinal surgery navigation system providing real-time surgery navigation for improved precision in spinal procedures. Developed in collaboration with Hadassah Medical Center.
• Periochip Pharmaceutical product for periodontal treatment; a Hadasit portfolio company success.
• Gamida Cell Omisirge FDA-approved blood cancer cell therapy (Omisirge) developed through collaboration with Prof. Amnon Peled at Hadassah. Represents first FDA-approved therapy from Hadassah research.
• NeuroGenesis NG-01 Novel cell therapy for progressive Multiple Sclerosis. Received FDA clearance for Phase IIb study. Hadasit portfolio company.
• Cell Cure Neurosciences (OpRegen) Biotechnology company developing cell therapy for degenerative retinal and macular diseases using human embryonic stem cells, based on Prof. Benjamin Reubinoff's technology. Subject of worldwide collaboration with Genentech.
• PlasFree Israeli plasma filter technology providing a cutting-edge solution for life-threatening bleeds. Received Ministry of Israel marketing approval.

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature3 records

Partnerships

Ten partnerships are on record, tiered core, major, minor and supporting.

• GenentechcoreStrategic or Co-development Partner · 17 December 2025Lineage Cell Therapeutics, with Hadassah origins, established exclusive worldwide collaboration with Genentech for development and commercialization of OpRegen RPE cell therapy for ocular disorders.
• TechsoMedmajorStrategic or Co-development Partner · 4 July 2025Hadasit and TechsoMed partnered to enhance cancer treatment with advanced AI-driven image-guided therapy solutions powered by big data from Hadassah.
• ModernamajorStrategic or Co-development Partner · 15 July 2024Sponsored research collaboration with Moderna on cCMV (congenital Cytomegalovirus) infection patterns.
• Pangea Biomed and Ultima GenomicsmajorStrategic or Co-development Partner · 7 June 2024Hadasit partnered with Pangea Biomed and Ultima Genomics for solid tumor cancer treatment research at Sharett Cancer Institute.
• IBM Alpha ZonecoreGTM or Marketing Partner · 1 October 2019IBM Alpha Zone powers the Hadassah Accelerator, a 6-month acceleration program for digital health and medical device startups. IBM provides specialists and resources to support portfolio companies.
• RecipharmcoreStrategic or Co-development Partner · 27 May 2018Recipharm partnered with Hadasit to deliver seamless clinical services, combining Recipharm's pharmaceutical development expertise with Hadassah's clinical research capabilities.
• BioMed X InstitutemajorStrategic or Co-development PartnerBioMed X Institute from Heidelberg is establishing a new AI/Pharma Innovation Lab in Israel in collaboration with Hadassah and Hadasit, building a world-class innovation ecosystem.
• MyBioticsminorStrategic or Co-development PartnerHadassah and MyBiotics collaborated for discovery of microbiome-based therapy for improving cancer immunotherapy.
• SHL TelemedicineminorStrategic or Co-development PartnerCollaboration for developing AI tools in telemedicine with Hadassah, Hebrew University, and SHL Telemedicine.
• AWS Cloud SolutionssupportingTechnology or IntegrationAWS Cloud Solutions participated as a partner in Smart Hospital digital infrastructure and patient data collaborations event.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Stanford University Office of Technology Licensing (OTL): Stanford's technology transfer office manages a deep pipeline of inventions from one of the world's leading research universities, licensing IP and forming spinouts - directly comparable to Hadasit's role commercializing Hadassah Medical Center research.
• Mass General Brigham Innovation: Technology transfer and venture arm of a major US academic medical center, commercializing inventions from Harvard-affiliated hospitals through licensing, spinouts, and partnerships - directly comparable in mission and operating model.
• Mayo Clinic Ventures: Commercialization arm of Mayo Clinic, focusing on licensing medical technologies, forming startups, and facilitating industry partnerships - directly comparable to Hadasit's tech transfer role at Hadassah.
• Johns Hopkins Technology Ventures (JHTV): Johns Hopkins University's technology transfer office, supporting faculty inventors through patenting, licensing, and startup formation - operates the same TTO model as Hadasit.
• Mount Sinai Innovation Partners (MSIP): Technology commercialization office of Mount Sinai Health System, focused on translating research into spinouts, licensing deals, and industry collaborations - comparable hospital-anchored TTO.
• Karolinska Innovations: Technology transfer and venture arm of Karolinska Institutet, commercializing life science and biotech research through licensing and spinouts - a direct peer for European academic medical TTO activity.
• Duke Office of Licensing & Ventures: Duke University's technology transfer office, managing IP, licensing, and startup formation from Duke research - operates an analogous academic TTO model.
• Cedars-Sinai Intellectual Property (IP): Cedars-Sinai Medical Center's technology transfer function, focused on commercializing medical innovations and forming startup companies - directly comparable hospital-anchored TTO.
• Yeda Research and Development Co. Technology transfer arm of the Weizmann Institute of Science in Israel, with a large portfolio of life sciences and biotech spinouts - the most direct Israeli peer to Hadasit given shared geography and mission.

Broad incumbents

• Bayer Co.Lab / Pharma incubator programs (industry-side accelerators): Large pharma-backed accelerator and partnership programs that source early-stage assets from academic medical centers - comparable as an alternative path pharma takes to access academic pipelines that compete with Hadasit's offerings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/hadasit

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hadasit